Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
upacicalcet (EA Pharma Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- EA Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Upacicalcet (also known as upasicalcet) is an intravenous small-molecule calcimimetic that acts as a positive allosteric modulator of the calcium-sensing receptor (CaSR). It was originally created by Ajinomoto Pharmaceuticals (now EA Pharma) and developed by Sanwa Kagaku Kenkyusho in Japan, where it was approved in June 2021 under the brand name Upasita for the treatment of secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. Pathalys Pharma, in collaboration with Launch Therapeutics, is developing upacicalcet globally outside of Japan and Asia, with Phase III clinical trials completed in the United States and Europe. By directly binding to CaSR on parathyroid cells, upacicalcet suppresses the excessive secretion of parathyroid hormone (PTH) and lowers blood PTH levels, while demonstrating a lower risk of gastrointestinal side effects and hypocalcemia compared to oral calcimimetics.
- Brand names
- Upasita
- Other names
- upacicalcetupacicalcet sodiumupacicalcet sodium hydrateupasicalcet
02
Targets
CaSR (Extracellular calcium-sensing receptor)
Beyond the preview
Go deeper on upacicalcet (EA Pharma Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on upacicalcet (EA Pharma Co., Ltd.).